Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$6.58M, compared with -$22.1M a year earlier. Trailing-twelve-month operating income was $75.79M.

Context

  • Operating income amounted to 15.0% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Operating income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 1 analysts of -$218.56M (-462.6%) for the fiscal year ending Dec 2026, a slowdown from the +10.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.58M-107.7% QoQ
Last fiscal yearDec 2025
$60.27M+10.8% YoY
LTMMar 2026
$75.79M+289.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70.2%-834.9%-905.1 pp
1 year+10.8%-462.6%-473.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
60.27M USD
Year-over-year change
+10.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +289.6% is the highest of 10, against a peer median of -35.7%.
  • Operating income amounts to 18.1% of revenue for ESPR, versus a peer median of 22.0%.
ESPR Competitors
Operating Income for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ESPREsperion Therapeutics, Inc.LTM Mar 2026$75.79M USD+289.6%—18.1%
EBSEmergent BioSolutions Inc.LTM Mar 2026$71.2M USD+171.3%—10.5%
SIGASIGA Technologies, Inc.LTM Mar 2026$20.64M USD-63.4%-17.8%22.0%
SNDLSNDL Inc.LTM Mar 2026-CA$7.42M CAD+93.1%—0.8%
OFIXOrthofix Medical Inc.LTM Mar 2026-$33.28M USD+68.0%—4.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$47.93M USD-53.5%——
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$55.89M USD-35.7%—111.2%
ABSIAbsci CorporationLTM Mar 2026-$128.54M USD-13.6%—7000.8%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$201.81M USD-41.3%——
RGNXREGENXBIO Inc.LTM Mar 2026-$256.69M USD-63.1%—292.3%
Peer median (excluding ESPR) —-35.7%-17.8%22.0%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.